AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01900912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLTS
Description: The goal of CLTS is to obtain Open Defecation Free (ODF) villages. CLTS aims to trigger the community's desire for change, propel them into action and encourage innovation, mutual support and appropriate local solutions, in order to foster greater ownership and sustainability. The phases are: pre-triggering (a group of trained-CLTS people visit the community and request a date to discuss sanitation-related issues for the following days), triggering (people are made to express their views on sanitation issues and their needs), monitoring (involves visits of the community twice a week for a period of 1-3 months) and certification (an external committee evaluates the village for certification as an ODF community).
Study NCT00917293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxal 5'-Phosphate
Description: Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.
Study NCT00917293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 pills, po bid.
Study NCT02094768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reduced Fat Milk
Description: Subjects will be provided with and instructed to consume the equivalent of 20oz. reduced fat milk per day for 3 weeks
Study NCT01086436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix ™
Description: Oral, single dose
Study NCT01086436 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, single dose
Study NCT02094768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar Sweetened Soda
Description: Subjects will be provided with and instructed to consume 2 cans (24oz) of sugar sweetened soda per day for 3 weeks
Study NCT03786627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined NMES and motor control
Description: This group will receive the neuromuscular electrical stimulation using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral lumbar multifidus muscles. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total stimulation time is 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. It is believed to restore the motor units in individuals with arthrogenic muscle inhibition. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
Study NCT03786627 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Motor control and placebo NMES
Description: This group will the neuromuscular electrical stimulation without turning the electrical current for 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
Study NCT00763009 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dipyridamole
Description: 0.28mg/kg over 4 minutes intravenously x three doses; totalling 0.84mg/kg intravenously
Study NCT01777672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary and oral hygiene recommendations
Study NCT01612871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen, Letrozole , Anastrozole, Exemestane
Description: Current first line metastatic hormone therapy treatment in hormone dependent breast cancer :~Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day
Study NCT01777672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and oral hygiene recommendations
Study NCT01777672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral TRPV1 agonist
Description: Patients will receive the administration of a TRPV1 agonist (natural capsaicin) supplement before each meal, 3 meals/day, 5 days/week for 2 consecutive weeks. The TRPV1 agonist will be provided by the pharmacy of the center.
Study NCT03798119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Subjects in this group will switch prior nucleot(s)ide analogs to Tenofovir Alafenamide 25 mg/day for 96 weeks
Study NCT00495040 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiotherapy
Description: 87.5 CGE with 2.5 Gy/fraction for 35 treatments
Study NCT03919071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT03919071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Given PO
Study NCT03919071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study NCT03919071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01777672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pharyngeal electrical stimulation
Description: Includes neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during 1 week, done at the same center.
Study NCT01777672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical stimulation
Description: Trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
Study NCT03919071 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT03919071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study NCT03131427 — intervention group
Intervention type: DRUG
Intervention: Standard of care
Description: Standard of care according to the updated national and/or international guidelines
Study NCT00812266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan + cisplatin
Description: topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W
Study NCT00812266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide + carboplatin
Description: Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W
Study NCT02687074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: patients treated with high flow nasal cannula
Study NCT02687074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV
Description: patients treated with noninvasive ventilation
Study NCT03859466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Therapy
Description: The cardiac shockwave system consists of a table-top device (Nonvasiv Medical GmbH, Konstanz, Germany) and a sterile single-use applicator releasing electrohydraulic shockwaves (Heart Regeneration Technologies GmbH, Innsbruck, Austria). Prior to use, the applicator is inserted into a sterile cover containing ultrasound gel. In order to ensure acoustic coupling between the applicator and the myocardium, continuous saline rinsing is applied throughout the procedure.
Study NCT00115726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide
Description: for patients on chronic furosemide therapy, patients are randomized to furosemide (at their previous dose) or placebo (given in identical form to ensure masking)
Study NCT00115726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will be given placebo capsules (identical to experimental arm in color) at the equivalent dose as to their chronic furosemide therapy.
Study NCT02649803 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: asthma APP
Description: Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the nearest community hospital or Shanghai Children's Medical Center, whichever is nearer to the subject's home, for their future onsite visits (V2-V5). The patient's caregiver will be instructed to install the asthma APP at their smart phone and learn how to use this APP.
Study NCT04053348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home-based rehabilitation program using mobile app
Description: Home-based rehabilitation program
Study NCT04053348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program using mobile app
Description: Home-based rehabilitation program
Study NCT01729377 — intervention group
Intervention type: OTHER
Intervention: Interview
Study NCT00533273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase clostridium histolyticum
Description: Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.
Study NCT00533273 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: collagenase clostridium histolyticum
Description: Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.
Study NCT01168557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EIT (Electrical Impedance Tomography)
Description: EIT measurement; concomitant to stress echocardiography (about 45 minutes) EIT measurements (1 minute) are performed at rest, at low dobutamine stress, at peak and at relaxation
Study NCT00662740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/Salmeterol QD
Description: Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
Study NCT00662740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
Study NCT00662740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol Inhalation Powder, hard PE capsule
Study NCT00662740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium/Salmeterol QD+ Salmeterol
Description: Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
Study NCT00662740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium (Spiriva®)
Description: Tiotropium, Spiriva®
Study NCT00262964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: Subjects randomized to Niacin therapy will be treated with Niacin at night for 16 wks to reduce plasma free fatty acid concentrations. The dose of medication will be gradually increased: 500 mg/day during week 1, 1000 mg/day during week 2, 1500 mg/day during week 3, and 2000mg/day during weeks 4-16.
Study NCT00262964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Description: Subjects randomized to fenofibrate will be treated with 200 mgs per day for eight weeks.
Study NCT00262964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects randomized to placebo will be treated with one placebo pill per day for eight weeks.
Study NCT02996682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily
Study NCT02996682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Capsules administered orally in a divided daily dose
Study NCT01929642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study NCT01929642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT03843593 — intervention group
Intervention type: BEHAVIORAL
Intervention: Demographics Questionnaire
Description: A brief questionnaire will collect basic demographic information (i.e., age, gender, racial background, ethnicity, employment status, marital status) at time of enrollment.
Study NCT03843593 — intervention group
Intervention type: BEHAVIORAL
Intervention: Adjuvant Treatment Beliefs Scale10
Description: This brief PRO measure asks patients to indicate the likelihood, using a 5-point Likert type scale (1 \[definitely not\], 2 \[probably not\], 3 \[maybe\], 4 \[probably\], 5 \[definitely\]) of six positive (e.g., reduced risk of recurrence, greater chance of being cured) and five negative outcomes (e.g., side effects, health status) of adjuvant treatment.
Study NCT03843593 — intervention group
Intervention type: BEHAVIORAL
Intervention: Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11
Description: FACT-M is a 51-item patient-self report measure for the assessment of quality of life (QOL) in patients with American Joint Committee on Cancer stages I through IV melanoma.
Study NCT02009241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Study NCT03843593 — intervention group
Intervention type: BEHAVIORAL
Intervention: Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13
Description: FACIT-TS-G is a brief, 8-item self-administered measure designed to assess general treatment satisfaction in patients.
Study NCT03843593 — intervention group
Intervention type: BEHAVIORAL
Intervention: Decisional Regret14
Description: This is a set of 5 questions examining level of regret for treatment decisions (in this case, decision to pursue adjuvant therapy), with answers scored on a 5-point Likert-type scale (i.e., 1 \[Strongly Agree\], 2 \[Agree\], 3 \[Neither Agree Nor Disagree\], 4 \[Disagree\], 5 \[Strongly Disagree\].
Study NCT03843593 — intervention group
Intervention type: BEHAVIORAL
Intervention: Clinician Preference for Treatment
Description: This is a single item to be completed by Medical Oncologists that will indicate their preference as to whether they prefer that their patient accepts adjuvant therapy.
Study NCT00735904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: AG-013736 5 mg tablets orally, twice daily, until disease progression
Study NCT00735904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m\^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles
Study NCT02850419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoDox (Thermally Sensitive Liposomal Doxorubicin)
Description: A dose of 40 mg/m2 will be administered at each cycle for a total of 6 cycles. ThermoDox will be administered in conjunction with hyperthermia.
Study NCT00735904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m\^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles
Study NCT03333291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fecal suspension
Description: helathy donor fecal suspension administered by duodenal scope
Study NCT02850419 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.
Study NCT02850419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Superficial Hyperthermia
Description: Thermal dose is an one-hour treatment at a temperature between 40 and 43 degrees Celsius at the target site.
Study NCT03287180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Community Reinforcement Approach (A-CRA)
Description: The A-CRA is a modified version of the Community Reinforcement Approach for adolescents and transitional age youth. The A-CRA treatment protocol consists of nineteen procedures designed to promote positive behavior change directed towards prosocial activities and engagement in the individual's community. A community can include but is not limited to: social and peer activities, family interaction, and work or school environments. Some of the highlighted procedures include relapse prevention, sobriety sampling, problem solving, and communication skills. There are also combined parent/and or couples relationship sessions with the young adult. In the current study, 12-weeks of A-CRA treatment will be provided to the intervention group.
Study NCT03287180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination of buprenorphine/naloxone 4/1
Description: Buprenorphine is a partial agonist at mu-opioid receptor, an antagonist at kappa-opioid receptor. Naloxone is an antagonist at the mu-opioid receptor. Buprenorphine/naloxone requires the use of an induction to avoid the risk of withdrawal. Participants are instructed not to use opioids for at least 10 hours prior to first dose. Once symptoms of withdrawal score a minimum of 7 on the Clinical Opiate Withdrawal Scale (COWS), the first dose of 4/1 mg will be given. Participants will be monitored for an hour. An additional 4/1 mg dose can be provided to a dose that suppresses withdrawal effects. The physician then provides a prescription for 8/2-16/4 mg for Day 2. Doses can be adjusted with a maximum of total 24/6 mg/day. The target daily dose is 16/4 mg.
Study NCT03287180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of buprenorphine/naloxone 4/1
Description: Buprenorphine is a partial agonist at mu-opioid receptor, an antagonist at kappa-opioid receptor. Naloxone is an antagonist at the mu-opioid receptor. Buprenorphine/naloxone requires the use of an induction to avoid the risk of withdrawal. Participants are instructed not to use opioids for at least 10 hours prior to first dose. Once symptoms of withdrawal score a minimum of 7 on the Clinical Opiate Withdrawal Scale (COWS), the first dose of 4/1 mg will be given. Participants will be monitored for an hour. An additional 4/1 mg dose can be provided to a dose that suppresses withdrawal effects. The physician then provides a prescription for 8/2-16/4 mg for Day 2. Doses can be adjusted with a maximum of total 24/6 mg/day. The target daily dose is 16/4 mg.
Study NCT04285775 — intervention group
Intervention type: DEVICE
Intervention: Application of device which monitors for bleeding - Blood Warning Technology with Continuous Hemoglobin sensor (BWATCH)
Description: A stand-alone disc-shaped device (approximately 5 cm in diameter and \<1 cm thick) which can be placed over dressings. Once switched on and put in place, continuous monitoring for bleeding takes place. Detection occurs in 2 phases. First, the system monitors for the appearance of fluid in the dressing by detecting a change in capacitance. Next, a light sensor differentiates blood from other fluids by detecting that a unique spectrum of light (525nm) is absorbed, a property unique for hemoglobin. The presence of fresh blood triggers a loud alarm, alerting medical staff to attend to the patient. The device can be used over transparent plastic dressings and does not require direct contact with blood.
Study NCT03030963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equal ratio ventilation(ERV)
Description: Set the inspiratory to expiratory ratio 1:1 during mechanical ventilation
Study NCT03030963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: I:E Ratio 1:2
Description: Set the inspiratory to expiratory ratio 1:2 during mechanical ventilation
Study NCT02012530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HA
Description: HA is widely applied in clinical practice with good results in many studies. HA forms part of the inflammatory process that can lead to the regeneration of cartilage in defective areas of the knee.
Study NCT02012530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: PRP uses reparative growth factors taken from the patient's own blood to create an environment in the knee conducive to wound healing that can fill cartilage defects. It's autologous origin, easy preparation and safety profile makes it a potentially ground breaking treatment option for knee cartilage defects and osteoarthritis.
Study NCT01675232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soak and smear
Description: Corticosteroid ointment applied to wet skin once a day and dry skin once a day.
Study NCT01675232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Smear
Description: Corticosteroid ointment applied to dry skin twice a day.
Study NCT00819741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
Study NCT00819741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily